Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
Yann Echelard
Advertisement
Yann Echelard, PhD is vice president of research and development at GTC Biotherapeutics, Inc.
Articles by Yann Echelard
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Regeneron's Libtayo Earns CHMP Nod for Expanded EU Dosing
2
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
3
Biomarker Testing Gaps Can Stall Targeted Oncology Therapy, BMS’s Dr Pennell Says
4
The BioPharm Brief: New Approval, Pediatric Progress, and Durable Remission
5